There has been great recent interest in the medical and statistical literature in the assessment and validation of surrogate endpoints as proxies for clinical endpoints in medical studies. More recently, authors have focused on using meta-analytical methods for quantification of surrogacy. In this article, we extend existing procedures for analysis based on the accelerated failure time model to this setting. An advantage of this approach relative to proportional hazards model is that it allows for analysis in the semi-competing risks setting, where we constrain the surrogate endpoint to occur before the true endpoint. A novel principal components procedure is developed for quantifying trial-level surrogacy. The methods are illustrated by application to data from several studies in colorectal cancer. A very interesting finding is that the proposed methods suggest a greater level of trial-level surrogacy relative to what has been previously reported.
Introduction
Biomedical researchers, and particularly those in the pharmaceutical industry, have great interest in using surrogate markers, if they can be shown to be valid. When the true endpoints are rare, occur later or are very expensive, the use of valid surrogate markers can substantially reduce clinical trial duration and size, lower the trial's expense and lead to earlier decision making.
Many paradigms have been put forward for the assessment of surrogacy; a recent account can be found in the book by Burzykowski et al. (2005) . Historically, the first criterion, or rather set of criteria, for surrogacy was proposed by Prentice (1989) . Critiques of the Prentice criteria have been given by Day and Duffy (1996) , Begg and Leung (2000) and Berger (2004) . Alternative measures to the Prentice criterion have been proposed by several authors (Freedman et al., 1992; Buyse and Molenberghs, 1998; Wang and Taylor, 2002 ).
The above-described work was developed in the context of a single study. More recently, many researchers have begun to look at surrogacy in the multi-trial or meta-analytical setting (e.g., Daniels and Hughes, 1997; Gail et al., 2000; Burzykowski et al. 2005, Ch. 7, 9-10) .
Measures of surrogacy here are classified as being trial-level versus individual-level. We define these measures of surrogacy in Section 2.2.
As in Ghosh (2008 Ghosh ( , 2009 , we focus on the situation where both the surrogate and true endpoints are time to events. Methods for assessing surrogacy based on the proportional hazards model and the accelerated failure time model have been proposed by Burzykowski et al. (2001) and Ghosh (2008) . However, if the goal is to have surrogate endpoints that occur sooner than the true endpoint so that the study duration is potentially shorter, then a conceptually appealing framework to consider is that of semi-competing risks data (Fine et al., 2001; Ghosh, 2006 Ghosh, , 2009 . We define the data structure in Section 2.2; the basic idea is that the region where the time to the surrogate endpoint is less than the time to the true endpoint is the relevant region for making inferences. Ghosh (2009) recently evaluated many existing measures of surrogacy using a single study for the semi-competing risks data structure. However, he only dealt with the situation of a single study. Given the increasing popularity of the meta-analytic framework described above, it is of interest to extend the semi-competing risk framework to this setting as well. Burzykowski et al. (2001; Chapter 11) describe methods for assessment of surrogate endpoints in the bivariate failure time setting, focusing primarily on the proportional hazards model. However, they give less attention to the accelerated failure time model and do not account for the semi-competing risks structure.
In this article, we consider hierarchical models for meta-analysis based on the accelerated failure time model for bivariate survival data, both ignoring as well as incorporating the semi-competing risks data structure. The methodology will be illustrated using data from a colorectal meta-analysis, a differing set of which was previously considered by Sargent et al. (2005) . In the work of Burzykowski et al. (2005) , they use a two-stage approach in which they estimate dependence at the lower (second) level using a copula model (Nelsen, 1999) . Based on the estimate of the dependence parameter, they then estimate the relevant parameters at the higher (first) level using a weighted regression model. Their modelling was primarily based on proportional hazards, while we consider the accelerated failure time model here. The structure of the paper is as follows. In Section 2, we will describe the motivating study and define the appropriate data structures. We then describe the probability models and estimation and inference procedures in Section 3. Our proposed methodology is applied to the real dataset in Section 4. Finally, we conclude with some discussion in Section 5.
Preliminaries and Background

Motivating Study: meta-analysis of colorectal cancer clinical trials
Using several surrogacy methods, Sargent et al. (2005) assessed disease-free survival as a potential surrogate endpoint for overall survival in colon cancer adjuvant trials. They were interested in assessing the effect of fluorouracil-based treatment on these outcomes and performed a pooled analysis of individual-level data on 20898 patients from 18 phase III trials. They were also interested in determining if disease-free survival at earlier time points would be predictive of overall survival at a later point in time (e.g., if disease-free survival at 2 years was predictive of overall survival at four years). There was substantial variation in the length of follow-up of patients from the individual trials, so all subjects were censored 8 years from randomization across the individual studies. Sargent et al. (2005) presented a comparison of a variety of surrogate endpoint methods with goal of having robust findings that were not sensitive to assumptions from any one approach. They found a strong association between disease-free survival assessed after a median follow-up of three years with overall survival assessed after five years median followup.
The strong correlation between DFS and OS was both within individual trials as well as between trials. The measures that they used for this assessment will be described in Section 2.2. Based on the findings, Sargent et al. (2005) conclude that "DFS can be considered an appropriate primary end point in the setting of clinical trials in adjuvant colon cancer."
One issue that is apparent from the definition of disease-free survival is that it is in fact a composite endpoint. If S denotes time to colorectal cancer recurrence, and T denotes time to death, the surrogate endpoint proposed by Sargent et al. (2005) is in fact S ∧ T , where a ∧ b denotes the minimum of two numbers a and b. As explained in Sargent et al. (2005) , for the study population, 80% of deaths were preceded by recurrence, so in fact the DFS endpoint is mostly dominated by recurrence. However, an alternative approach that is potentially appealing is the semi-competing risks paradigm, in which we consider a latent time to recurrence for all individuals and study the association between that with time to death.
In this article, we deal with a subset of the data considered by Sargent et al. (2005) .
In particular, we analyze data from 12 studies that are available; details of the patient population of the studies are given in arm. There is also some heterogeneity in the followup times. The shortest and longest median followup times across the studies differ by an approximate factor of two. Table 2 summarizes the study-specific results of log-rank statistics comparing the two groups for three type of endpoints; time to recurrence, time to death and time to first event. For the surrogacy analysis in the absence of competing risks, we will use the first two endpoints, while the semi-competing risks analysis will require use of the second two endpoints. For multiple reasons (e.g., differing censoring rule, differing availability of followup, etc.), the results in Table 2 may differ from those in the primary clinical manuscript from each trial.
Measures of Surrogacy in the Meta-Analytical Framework
In the setting of multiple trials, for each trial, let (S ij , T ij , Z ij ) represent the surrogate markers, true endpoints and treatment group for individual j in trial i. Assume for the moment that S ij and T ij are continuous and are uncensored. Buyse et al. (2000) suggested a bivariate mixed model approach for joint analysis of (S ij , T ij ):
where the error terms
and
In (2) and (3), MVN refers to the multivariate normal distribution. The parameters (α 0 , α 1 , γ 0 , γ 1 ) in (1) refer to fixed effect parameters for the intercept and the treatment effects on the surrogate and true endpoints. The parameters (a 0i , a 1i , r 0i , r 1i ) in (1), in conjunction with the distributional assumption in (3) imply a random effects structure of the treatment effects on the true and surrogate endpoints across the multiple trials. Buyse et al. (2000) developed measures of between-trial and within-trial association.
Notions of surrogacy based on (4) and (5) can now be developed. A surrogate for which (5) is one is a perfect surrogate at the individual level. This says that the surrogate and true endpoints are perfectly correlated within an individual subject. A surrogate endpoint for which (4) is one is a perfect surrogate at the trial level. Buyse et al. (2000) and Gail et al. (2000) have argued that the between-trial association was a far more important characteristic of the surrogate than the within-trial measure for predicting the treatment effect in the new trial.
Before describing the observed data structures we deal with, we note that in the presence of censoring, the intercept terms and associated random effects will be difficult to estimate.
We therefore will set a 0 = a 0i = r 0 = r 0i = 0 here and in the sequel; we will correspondingly allow the error terms to not have mean zero. Another issue is that estimation of the individual-level measure of surrogacy using (5) is more challenging due to the presence of censoring. We will instead use copula models (Nelsen, 1999) , which we discuss in Section 3.4.
Observed Data Structures and AFT Regression Model
Let a ∧ b denote the minimum of two numbers a and b. Define I(A) to be the indicator function for the event A. Let S denote time to the surrogate endpoint, T the time to the clinical endpoint and C time to independent censoring. Assume that the joint distribution of (S, T, C) is continuous. In this article, we focus on the situation where the true and surrogate endpoints are both times to event. Let Z be the indicator for treatment group (0 = control; 1 = treatment). We make the assumption that (S, T ) is independent of C given Z. The data
. . , I; j = 1, . . . , n i ). Note that there are two indices; the first indexes study, while the second indexes individuals within a study. We consider two situations:
1. For a fixed i, the data are a random sample from (X, δ
2. For a fixed i, the data are a random sample from (X, δ X , Y, δ Y , Z), where X = S∧T ∧C,
For the first data structure, we have the usual independent censoring of (S, T ) by C, the time to the independent censoring. By contrast, in the second data structure, S is censored by the minimum of T and C and not just by C. However, T is only subject to independent censoring. This type of data structure has been called semi-competing risks in the recent statistical literature (Fine et al., 2001) . For this setting, the following distributions are of interest:
(a) The distribution of the surrogate endpoint in the absence of both the true endpoint and independent censoring, potentially adjusting for covariates; (b) the distribution of the true endpoint in the absence of independent censoring, potentially adjusting for covariates;
Because we wish to adjust for the dependent censoring by the true endpoint in (a), this will complicate estimation and inference procedures. Another unique feature of the semicompeting risks problem is that we wish to make inference on the region S ≤ T . This is called the "wedge region" and seems pertinent for our context. The wedge region represents when the surrogate endpoint will have occurred before the true endpoint. In the example considered in the paper, we would be interested in determining the association between time to recurrence and time to death.
We will be fitting the following models to each study:
and log S = αZ + 2 ,
where α and β are scalar regression coefficients and 1 and 2 are mean-zero error terms.
These are known as accelerated failure time models and are a useful alternative to proportional hazards model. They directly model the failure times. If we make no constraints on the ordering and censoring of S and T , then models (6) and (7) can be treated as marginal models and estimated separately. However, this cannot be done when there is semi-competing risks. In particular, the semi-competing risks structure imposes a constraint on the joint distribution of ( 1 , 2 ) so that estimation of β and α cannot be decoupled easily.
3 Proposed Methodology
General algorithm for trial-level surrogacy
We are interested in estimating individual and trial-level measures of surrogacy, analogous
to (4) and (5), based on the observed failure time data for the two data structures described above. We suggest the following two-step strategy for estimation:
(a) Estimate β i and α i for each study using methods for the accelerated failure time model.
Call the resulting estimatorsβ i andα i .
(b) Based on a measurement error modelling approach, regressβ i onα i .
We refer to steps (a) and (b) as within-trial estimation and between-trial estimation. Measures of within-trial surrogacy will be calculated using the output in (a). Based on the output of (b), we will be in a position to calculate between-study measures of surrogacy.
for the observed data. We will describe methods of estimation for each of these steps in turn. For (a), the procedure will be different depending on whether or not we have semicompeting risks data. The procedure for step (b) is related to the development in Chapter 11 of Burzykowski et al. (2005) .
Within-trial estimation in the absence of semicompeting risks
For this scenario, there is no dependent censoring for either outcome, so standard methods for estimation in the accelerated failure time model could be used. In Ghosh (2008) , the method of Jin et al. (2003) was used for estimation of the regression coefficients in the AFT model. It uses linear programming, followed by a stochastic perturbation of a certain weighted estimating function, to estimate the regression parameters of the AFT model.
Given some of the sample sizes for the datasets presented in Table 1 , we found it practically infeasible to use this algorithm.
Therefore, we resort to an estimation procedure developed by Buckley and James (Buckley and James, 1979) and implemented in the R package Hmisc. The basic idea is that an estimator forβ in the AFT model is calculated using an iterative least-squares estimator based on the response variable y * ,where y * = T * ∆/Ĝ C (T * ), ∆ is the vector of censoring indicators for all individuals, T * is the vector of right-censored failure times for all individuals, andĜ C is the Kaplan-Meier estimator of the censoring distribution. In Appendix A,
we provide a sketch of the algorithm.
Within-trial estimation in the presence of semicompeting risks
Let us now consider the situation with competing risks. Because of the dependent censoring between S and T , it is not possible to estimate the treatment effects on the two outcomes separately. We first consider the treatment effect on the true endpoint. To estimate this effect, one can use the ordinary log-rank estimating function (Louis, 1981) :
where
For the estimation of α, we must take into account the dependent censoring of S by T .
The dependent censoring is adjusted for through use of an artificial censoring technique (Lin et al., 1996) . We artificially trim the transformed surrogate endpoint time by a factor that allows for valid comparison between the two treatment groups. Define η = (α, β). This leads to the following estimating equation for estimation of η:
zero-crossing of α from setting U 2 (η) = 0, whereη = (α,β). The role of d is to artificially censor observations in one of the treatment arms depending on the relative magnitudes of the treatment effects on the true and surrogate endpoints. Note that the estimated treatment effect on the true endpoint is accounted for in the estimator of the treatment on the surrogate endpoint. This is quite different from the estimation in the previous section, which decouples the estimation of the treatment effects on the true and surrogate endpoints.
Ghosh (2009) proposed one type of resampling method for estimating the variancecovariance matrix ofη. Such a resampling is needed because consistent estimation of the variance of the regression coefficients requires complicated nonparametric estimation of the density of the errors and its derivative. We take an alternative approach based on resampling recently proposed by Zeng and Lin (2008) . The algorithm works as follows:
1. Generate observations G ≡ (G 1 , G 2 ), two independent and identically distributed N (0, 1) random variables.
Calculate n
3. Repeat steps 1 and 2 B times.
4. Regress n −1/2 U 1 (β+n −1/2 G 1 ) on G 1 across the B datasets. Similarly, Regress n −1/2 U 2 (η+ n −1/2 G) on G 1 and G 2 across the B datasets.
5. Estimate the variance-covariance matrix of n 1/2 (η − η 0 ) asÂ −1VÂ−1 , where the first row ofÂ is the slope estimate from the first regression in the previous step, while the second row ofÂ are slope estimates from the second regression in the previous step.
The estimateV is found by calculating the variance-covariance matrix of the Modifying the arguments in Zeng and Lin (2008) , we show in Appendix B that this algorithm provides a consistent estimator of the variance-covariance matrix of n 1/2 ( η − η 0 ). In our experience, we have found this algorithm to be much faster than that of Ghosh (2009) .
Between-trial estimation: linear regression and measurement error modeling
Given estimates (α j ,β j ), j = 1, . . . , J, we now seek to estimate the relationship between the two regression coefficients. As discussed in Chapter 11 of Burzykowksi et al. (2005) , one can either assume that there is no error in the estimated regression coefficients or that there is error. The assumption made at this stage will then dictate the appropriate method of analysis used. If the regression coefficients are presumed to have no error, then one can fit either an unweighted or weighted (by study sample size) regression ofβ onα. The R 2 value from this analysis then becomes the estimate of R 2 trial and is used for assessing trial-level surrogacy. If one instead wishes to allow for error in the estimates, then some measurement error modeling approaches are described in Chapter 11 of Burzykowski et al. (2005) . We note that there is in fact an approximate equivalence between the models described there with those for principal components analysis. The models being fit in Section 11.3 of Burzykowski et al. (2005) can be formally expressed as
for j = 1, . . . , J. where Σ is an unknown 2 × 2 variance matrix, and U is an unspecified 2 × 1 vector. This model can be interpreted in terms of latent factor models for the covariance matrix of (α j ,β j ), j = 1, . . . , J. In the current version, the model is nonidentifiable from the observed data because of the complete confounding of U with Σ. Therefore, we make the assumption that Σ = σ 2 I. As demonstrated in Tipping and Bishop (1999) , the principal components of the covariance matrix of (α,β) is an approximate maximum likelihood estimator in this model. Based on this result, our proposal is to calculate the principal components of the estimated variance-covariance matrix of (α j ,β j ), j = 1, . . . , J and to use the proportion of variance explained by the first eigenvector as our estimate of R estimated coefficients in (10). In the data example presented here, the bootstrap approach used did not affect the 95% CI (data not shown). Note that the approach described here can work in either the presence or the absence of semi-competing risks; what is required as an input to the algorithm is the estimates of α and β from each individual study.
General algorithm for individual level surrogacy
As alluded to in Section 2.2., assessing surrogacy at the individual level using an R 2 criterion is not typically appropriate because of the presence of censoring. The approach we take instead is to probabilistically model dependence using copulas (Nelsen, 1999) .
Let us first consider the situation of no semi-competing risks. LettingH(s, t) ≡ P r(S > s, T > t) be the joint survival distribution of (S, T ), a copula model decomposes the joint distribution into the marginal components:
where C is the copula function, θ is a dependence parameter, andF S andF T are the marginal survivor functions of S and T . The most commonly chosen copula model for multivariate survival data is called the Clayton-Oakes model (Clayton, 1978; Oakes, 1986) and is given by
with θ > 0. The following property is implied by the Clayton-Oakes model: θ(t, s) = θ, where
The function θ(t, s) is a measure of local dependence between S and T and is known as the cross-ratio function (Oakes, 1989) .
In the situation where we have to deal with competing risks, we still work with ClaytonOakes model. Fine et al. (2001) formulated the Clayton-Oakes model only for the upper wedge of the joint distribution of (S, T ) in the semi-competing risks setting. Fine et al. (2001) provided a closed form estimator of θ using modified weighted concordance estimating functions from Oakes (1982 Oakes ( , 1986 along with an asymptotic variance estimator.
We will use estimating equations to estimate the dependence parameters for the two situations (presence and absence of semi-competing risks). We calculate dependence parameters on a study-specific basis, so assume that we consider data from one study for the moment. Define e T (β) = log T − βZ and e S (α) = log S − αZ to be the population residuals corresponding to (6) and (7). In the situation in the absence of semi-competing risks, we estimate θ by the following formula:
For the semi-competing risks problem, the following estimator is used:
. . , n. Note that for both the non-and semi-competing risks setting, the estimator for the dependence parameter does not require any estimation of the marginal distribution functions. While there is efficiency loss relative to a two-stage pseudo-likelihood-type estimation procedure in the spirit of Shih and Louis (1995) , an advantage of the proposed estimation procedure is that it does not require estimation of the infinite-dimensional nuisance parameters. This becomes even more important in the situation where semi-competing risks is present. There, the marginal distribution of S is not even identifiable from the observed data. Variance estimates forθ andθ can be obtained using U-statistic theory (van der Vaart, 2000) and are described in Ghosh (2008 Ghosh ( ,2009 ).
Application to colorectal cancer data
We now apply the proposed methodologies to the colorectal cancer data described in Section 2. The first set of analyses assume that there is no semi-competing risks structure. The estimates of the regression coefficients of treatment on the true and surrogate endpoints, along with the associated standard errors, are given in Table 3 . Based on the table, we find that the effects of treatment on the surrogate endpoint tend to be larger than that on the true endpoint. There is also varying evidence about the significance of the treatment effects across the studies. For example, if one were to apply the concordance criteria of Begg and
Leung (2000) based on a significance level of 0.05, five of the 12 studies would meet this criterion. Next, we explored individual level surrogacy based on the Clayton-Oakes model.
Study-specific estimates of adjusted association can be found in Table 3 . The associated 95%
confidence interval was (0.905, 0.914) or (9.56, 10.74) on theθ scale. Next, we assessed triallevel significance. First, we performed an unweighted regression of the treatment effects. This yielded an R 2 of 0.89, with an associated 95% confidence interval of (0.73, 0.98). The analysis presumes that the estimated effects of the treatment on the true and surrogate endpoints are not measured with error. If instead an analysis assuming measurement error in both effect estimates is performed using the principal components analysis approach described in Section 3.4, then this yields a trial-level R 2 of 0.95, with an associated 95% confidence interval of (0.91, 0.99). Thus, we find that adjusting for the measurement error leads to much stronger evidence of trial-level surrogacy relative to ignoring it.
Next, we analyzed the data using semi-competing risks framework. This is done using the time to events of first event (disease-free survival) and death. The results are given in Table 4 . Note that while the treatment effects on death are in general qualitatively similar to those presented in Table 3 , the other regression coefficients are quite different from the non-semicompeting risks situation. Also, note that for many of the studies, the estimates of the two regression coefficients are effectively identical. This is because of the extremely strong correlation between the two event times and because of the fact that we are imposing the constraint S ≤ T . Table 5 summarizes the within-treatment arm estimates of the dependence between the two endpoints using the Fine et al. (2001) estimation procedure of the semi-competing risks copula dependence parameter. While the results there are forθ, these can be converted to Kendall's tau using the formulaτ =θ/(1 +θ). All of the Kendall's tau values in Table 5 are at least 0.9. If one were to calculate Wald statistics based on the estimates in Table 5 divided by their standard errors, their corresponding p-values (assuming a standard normal distribution under the null hypothesis) would be miniscule. However, we also find that imposing the constraint leads to greater evidence of trial-level surrogacy. Now we have a trial-level R 2 of 0.96, with an associated 95% confidence interval of (0.93, 0.99).
This interval is narrower and closer to one than that given in the previous paragraph. This is also greater than the trial-level R 2 reported in Figures 1 and 2 of Sargent et al. (2005) , although a direct comparison is not possible because of the nonoverlap in the datasets used.
Finally, we see that the adjusted correlation values tend to be greater in the semi-competing risks situation relative to the non-semicompeting risks situation. The only studies for which this is not the case is C03, and two of the NCCTG studies. For the latter two, a possible cause of the diminishing correlation might be the relative heterogeneity in the control group.
Discussion
In this work, we have extended the work of Ghosh (2008 Ghosh ( , 2009 ) to the multiple-study framework for assessing surrogacy. We consider both the usual bivariate censoring as well as the more structured semi-competing risks problem. The analysis of the motivating example using semi-competing risks methodology provided more compelling evidence for surrogacy than previous analyses of related datasets. Because the semi-competing risks explicitly builds in the constraint that S ≤ T , this suggests that colorectal cancer recurrence will be a very strong surrogate endpoint for death.
One of the practical issues alluded to in Chapter 11 of Burzykowski et al. (2005) regarding the assessment of trial-level surrogacy is whether to use linear regression models versus latent variable models. Given that there is error in the estimates of the treatment effects on the surrogate and true endpoints, we recommend the use of latent variable models in practice.
Much of the framework that has been described here uses measures of association to assess surrogacy. Of more recent interest has been the use of causal inference models to address the problem of surrogate endpoints (Frangakis and Rubin, 2002; Taylor et al., 2005; Greene and Joffe, 2008) . As described in Ghosh (2009) , it appears that the semi-competing risks data structure does not fit in well with the causal inference paradigm due to the wedge region constraint. Attempting to reconcile the two paradigms is currently under investigation.
We are in the process of making the software used to fit the proposed methods publicly available as an R package.
. . , n. Then the BuckleyJames estimating equation can be written
where ∆Ŝ KM denotes the increment in the Kaplan-Meier estimator. The BuckleyJames estimator is the solution to the above equation.
B. Validity of proposed resampling scheme
Assuming that the true (α, β) line in an interior point of a compact subspace of R 2 , and that E{U 2 (α, β 0 )} = 0 has a unique solution at zero, we can extend the approach of Ying (1993) to show that
where η ∈ N r (η 0 ) = w : |w − η 0 | < r for sufficiently small r > 0, and A is the asymptotic slope matrix of n −1 U(η 0 ). This asymptotic linear expansion of U is what is needed to apply the method of Zeng and Lin (2008) . Note: The table shows two-sample unweighted log-rank statistics for comparing the two treatment groups for each study. For the sake of reference, under the null hypothesis, the statistic should have an approximate chi-squared distribution with one degree of freedom. 
